Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High- vs Low-Dose Sirolimus in Kaposiform Hemangioendothelioma
NCT04775173Phase 2Completed
- Sponsor
- West China Hospital of Sichuan University
- Start
- Feb 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sirolimus in kaposiform hemangioendothelioma (KHE) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Proportion of patients achieving an objective response at 12 months. Started Feb 2021; status: completed.
02
Drugs
sirolimus
03
Conditions
kaposiform hemangioendothelioma (KHE)
Beyond the preview
Go deeper on NCT04775173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04775173.